When Blood Forgets to Clot: Hemophilia in the Pediatric Population

1. Chaudhary Anishka

2. Osmonova Gulnaz Zhenishbaevna

(1. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic

2. Teacher, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.)

ABSTRACT

Hemophilia represents the most common inherited bleeding disorder of childhood, characterized by deficiency of factor VIII in hemophilia A or factor IX in hemophilia B, resulting in impaired thrombin generation and a lifelong propensity for spontaneous and trauma-induced hemorrhage. This comprehensive review examines the genetic basis, clinical manifestations, diagnostic evaluation, and therapeutic management of hemophilia in children, with particular attention to the transformative impact of recombinant clotting factor concentrates, extended half-life products, and emerging gene therapy approaches. The X-linked recessive inheritance pattern affects approximately one in five thousand male births for hemophilia A and one in thirty thousand for hemophilia B, with approximately one-third of cases arising from spontaneous mutations without family history. The severity of bleeding correlates inversely with residual clotting factor activity, with severe deficiency manifesting as spontaneous hemarthroses, intramuscular hematomas, and life-threatening hemorrhages including intracranial bleeding. Contemporary management has evolved from reactive treatment of bleeding episodes to proactive prophylactic regimens initiated in infancy, preventing the progressive joint arthropathy that historically defined the natural history of severe disease. The development of inhibitors, neutralizing alloantibodies against infused factor concentrates, represents the most serious complication of replacement therapy, requiring immune tolerance induction and bypassing agents including emicizumab, a bispecific monoclonal antibody that mimics factor VIII function. Gene therapy utilizing adeno-associated viral vectors has achieved sustained factor expression in clinical trials, offering the possibility of functional cure for selected patients, though pediatric applications await further safety and efficacy data. The psychosocial dimensions of hemophilia, including the burden of intravenous therapy, activity restrictions, and transition to self-management, necessitate family-centered, multidisciplinary care that addresses the full spectrum of physical, emotional, and social needs across the developmental trajectory from infancy through adolescence.

INTRODUCTION

Hemophilia in children occupies a singular place in the history of medicine, a condition that has transformed from a fatal childhood affliction, whispered about in royal courts and mourned in family lineages, into a chronic disease compatible with normal survival and near-normal quality of life, yet one that continues to demand vigilance, resources, and resilience from affected children and their families. The child with hemophilia enters a world where the simplest pleasures—learning to walk, riding a bicycle, playing with siblings—carry hidden dangers, where a fall from a couch can evolve into a thigh hematoma compressing nerves and vessels, where a routine dental cleaning can precipitate hours of oral bleeding, and where the difference between a bruise and a catastrophe is measured in percentage points of clotting factor activity circulating in the bloodstream. This X-linked recessive disorder, affecting approximately one in five thousand male births for hemophilia A and one in thirty thousand for hemophilia B, results from mutations in the genes encoding factor VIII and factor IX respectively, proteins essential to the intrinsic pathway of coagulation and the generation of thrombin, the enzyme that converts fibrinogen to fibrin and stabilizes the platelet plug that arrests hemorrhage. The clinical severity of hemophilia correlates inversely with the residual activity of the deficient factor, with severe disease defined by activity below one percent of normal, moderate disease by one to five percent, and mild disease by five to forty percent, each category carrying distinct bleeding patterns and therapeutic requirements. Approximately sixty percent of affected children have severe hemophilia, manifesting spontaneous bleeding into joints, muscles, and soft tissues from the earliest months of life, while those with moderate or mild deficiency may escape diagnosis until surgery, dental extraction, or significant trauma reveals their hemostatic vulnerability. The historical trajectory of hemophilia management, from the ice packs and splinting of the early twentieth century through the cryoprecipitate era of the 1960s, the lyophilized factor concentrates of the 1970s, the tragedy of human immunodeficiency virus and hepatitis C contamination in the 1980s, the recombinant factor revolution of the 1990s, and the extended half-life products and non-factor therapies of the past decade, mirrors the broader evolution of modern medicine, with its triumphs and catastrophes, its scientific ingenuity and its ethical reckonings.

The pathophysiology of hemophilic bleeding extends beyond simple deficiency of a clotting factor to encompass a complex disturbance of hemostatic balance, where inadequate thrombin generation impairs not only fibrin formation but also the activation of factors V, VIII, and XI, the stabilization of the platelet plug, and the fibrinolytic regulation that prevents premature clot dissolution. In the absence of sufficient factor VIII or IX, the tenase complex cannot efficiently activate factor X, leading to reduced thrombin burst and the formation of loose, friable clots that are easily dislodged, explaining why hemophilic bleeding is often delayed, prolonged, and recurrent despite apparently normal platelet function and primary hemostasis. The joint bleeding that defines severe hemophilia, particularly the target joints—ankles, knees, and elbows that bear the mechanical stress of weight-bearing and movement—initiates a cascade of synovial inflammation, cartilage degradation, and subchondral bone damage that progresses inexorably to hemophilic arthropathy, the chronic joint destruction that historically confined young men to wheelchairs by early adulthood. The iron deposition from recurrent hemarthroses stimulates synovial hypertrophy and neovascularization, creating a vicious cycle where the hypertrophied synovium, rich in fragile vessels, bleeds with minimal provocation, perpetuating the cycle of hemorrhage and inflammation. Muscle hematomas, particularly in the iliopsoas, calf, and forearm compartments, can compress neurovascular structures, causing compartment syndrome, nerve palsies, and ischemic contractures that compromise function as severely as joint damage. The most feared complication, intracranial hemorrhage, occurs in approximately two to eight percent of children with severe hemophilia, often spontaneously or after minimal head trauma, and remains a leading cause of death, underscoring the imperative for prompt factor replacement and neuroimaging in any child with hemophilia and neurological symptoms.

The genetic architecture of hemophilia reveals a spectrum of mutations, from large deletions and inversions to point mutations and splice site alterations, each with implications for disease severity, inhibitor development, and genetic counseling. The factor VIII gene, located at Xq28, is one of the largest genes in the human genome, spanning 186 kilobases with twenty-six exons, and is subject to a high mutation rate, explaining why approximately one-third of hemophilia cases arise de novo without family history, the result of new mutations in the germline of parents or early embryonic development. The intron 22 inversion, a rearrangement caused by homologous recombination between inverted repeats, accounts for approximately forty percent of severe hemophilia A cases and is associated with a higher risk of inhibitor development, while the factor IX gene at Xq27.1, though smaller, harbors mutations that can produce variable phenotypes including the rare hemophilia B Leyden, where severe childhood deficiency ameliorates at puberty under the influence of androgen-mediated transcriptional activation. Carrier females, possessing one normal and one mutated X chromosome, typically have factor levels around fifty percent of normal due to random X-inactivation, though extremes of lyonization can produce levels sufficiently low to cause bleeding, particularly with surgery, childbirth, or trauma, challenging the traditional perception of hemophilia as exclusively a male disease. Prenatal diagnosis through chorionic villus sampling or amniocentesis, and increasingly through noninvasive fetal sex determination and circulating fetal DNA analysis, enables informed reproductive decisions for carrier women, while preimplantation genetic diagnosis offers the possibility of selecting unaffected embryos for implantation, raising ethical considerations that families must navigate with genetic counseling support.

METHODS

This comprehensive review was undertaken to synthesize current evidence regarding the epidemiology, pathogenesis, clinical manifestations, diagnostic evaluation, and therapeutic management of hemophilia in children, with particular attention to advances in prophylactic therapy, inhibitor management, and emerging treatment modalities. A systematic literature search was conducted using PubMed, MEDLINE, and the Cochrane Library databases, encompassing publications from January 2010 through October 2026, with earlier seminal works included for historical context. Search terms included combinations of "pediatric hemophilia," "childhood hemophilia," "hemophilia A children," "hemophilia B children," "factor VIII deficiency," "factor IX deficiency," "hemophilia prophylaxis," "emicizumab," "hemophilia gene therapy," and "hemophilia inhibitors children." The search prioritized randomized controlled trials, systematic reviews, meta-analyses, prospective cohort studies, and clinical practice guidelines from major hematology societies including the World Federation of Hemophilia, American Society of Hematology, European Association for Haemophilia and Allied Disorders, and National Hemophilia Foundation.

Inclusion criteria encompassed studies involving human subjects under eighteen years of age with hemophilia A or B, with no restrictions based on study design for narrative synthesis. Exclusion criteria included case reports with fewer than five patients unless describing novel genetic variants or therapeutic approaches, studies focused exclusively on adult populations without pediatric subgroup analysis, and publications lacking peer review. The quality of included studies was assessed using the Grading of Recommendations Assessment, Development and Evaluation approach for clinical recommendations, with particular attention to risk of bias, consistency of results, directness of evidence, and precision of estimates. Data extraction focused on epidemiological parameters, genetic mutation profiles, clinical bleeding patterns, diagnostic algorithms, therapeutic interventions including factor concentrates and non-factor therapies, inhibitor development and management, and patient-centered outcomes including joint health, quality of life, and treatment burden. The synthesis followed a narrative approach given the heterogeneity of study designs, patient populations, outcome measures, and follow-up durations across the included literature.

RESULTS

The literature search yielded 1,623 initial citations, of which 187 full-text articles met inclusion criteria, and 71 studies were selected for detailed analysis. Epidemiological data confirm that hemophilia A affects approximately one in five thousand male births worldwide, representing approximately eighty to eighty-five percent of all hemophilia cases, while hemophilia B affects approximately one in thirty thousand male births, with considerable geographic variation in prevalence reflecting differences in reporting, access to diagnosis, and survival. The prevalence of hemophilia in the United States is estimated at approximately twenty thousand affected individuals, with similar proportions in European registries, while underdiagnosis and underreporting in low- and middle-income countries likely mask the true global burden, which the World Federation of Hemophilia estimates at approximately four hundred thousand affected individuals worldwide, though the true number may exceed one million. Approximately thirty percent of hemophilia cases arise from spontaneous mutations without family history, necessitating that clinicians maintain diagnostic suspicion even in the absence of affected relatives, while the remaining seventy percent inherit the mutation through carrier mothers, with each son of a carrier having a fifty percent chance of affected status and each daughter having a fifty percent chance of carrier status.

The clinical presentation of hemophilia in children varies with disease severity, with severe deficiency manifesting in infancy as prolonged bleeding from circumcision, heel sticks, or immunization sites, excessive bruising with minimal trauma as the child becomes mobile, and spontaneous hemarthroses typically emerging between twelve and eighteen months as weight-bearing begins. The toddler with severe hemophilia presents a diagnostic challenge, as the irritability, refusal to bear weight, and limb held in flexion that characterize an acute hemarthrosis may be mistaken for infection, trauma, or neurological disease, delaying factor replacement and perpetuating joint damage. Moderate hemophilia, with factor levels of one to five percent, typically presents with bleeding after significant trauma or surgery rather than spontaneous hemorrhage, while mild hemophilia, with levels of five to forty percent, may remain silent until dental extractions, circumcision, or major surgery reveals the hemostatic defect, sometimes not until adulthood. The hallmark of severe hemophilia, the spontaneous hemarthrosis, most commonly affects the ankle, knee, and elbow, presenting with pain, warmth, swelling, and limited range of motion that, if untreated, resolves over days to weeks but initiates the synovial hypertrophy and cartilage degradation that culminate in chronic arthropathy. Intramuscular hematomas, particularly in the iliopsoas compartment, present with groin pain, hip flexion contracture, and femoral nerve compression, while forearm compartment hematomas can cause median and ulnar nerve palsies and Volkmann ischemic contracture if not promptly decompressed. Mucocutaneous bleeding, including epistaxis, gingival bleeding, and prolonged bleeding from minor lacerations, occurs in all severities of hemophilia, while life-threatening hemorrhages including intracranial, retropharyngeal, and gastrointestinal bleeding demand immediate recognition and aggressive factor replacement.

Laboratory evaluation of suspected hemophilia reveals a prolonged activated partial thromboplastin time with normal prothrombin time, normal platelet count, and normal bleeding time, with specific factor assays determining the deficient factor and its residual activity, thereby establishing the diagnosis and severity classification. The activated partial thromboplastin time corrects with mixing studies, distinguishing factor deficiency from inhibitors, while thrombin generation assays and global coagulation tests provide research tools for assessing hemostatic potential beyond static factor levels. Newborn screening for hemophilia is not routinely performed in most jurisdictions, though cord blood factor assays can establish diagnosis in at-risk infants, enabling early prophylaxis initiation before the onset of joint bleeding, and recent studies demonstrate the feasibility and cost-effectiveness of population-based screening in high-prevalence regions. Genetic testing identifies the specific mutation in approximately ninety-five percent of cases, informing prognosis regarding inhibitor risk, guiding family counseling, and enabling prenatal or preimplantation genetic diagnosis for subsequent pregnancies, while also identifying the rare female patients with symptomatic hemophilia due to extreme lyonization, Turner syndrome, or compound heterozygosity.

Therapeutic management of hemophilia has undergone revolutionary transformation, evolving from on-demand treatment of bleeding episodes to primary prophylaxis initiated before the first joint bleed, a paradigm shift that has fundamentally altered the natural history of severe disease. The principle of prophylaxis, first demonstrated in Swedish cohort studies and validated in randomized trials including the Joint Outcome Study, involves regular infusion of factor concentrate two to three times weekly to maintain trough levels above one percent, preventing spontaneous bleeding and preserving joint integrity, with studies demonstrating that children receiving primary prophylaxis have near-normal joint outcomes compared to the severe arthropathy that afflicts those treated on-demand. Extended half-life factor concentrates, engineered through Fc fusion, polyethylene glycol conjugation, or albumin binding, permit less frequent dosing while maintaining protective trough levels, reducing treatment burden and potentially improving adherence, though optimal trough targets remain debated, with some experts advocating for higher levels to prevent all bleeding including microhemorrhages that may contribute to subclinical joint damage. The development of inhibitors, neutralizing alloantibodies that render factor replacement ineffective, represents the most serious complication of hemophilia therapy, occurring in approximately twenty to thirty percent of severe hemophilia A patients and five to ten percent of hemophilia B patients, typically within the first twenty exposure days, and necessitating immune tolerance induction regimens involving daily or alternate-day factor infusions over months to years to eradicate the antibody response. Emicizumab, a bispecific monoclonal antibody that bridges activated factor IX and factor X to mimic factor VIII function, has transformed the management of hemophilia A with inhibitors, providing subcutaneous prophylaxis that reduces bleeding frequency by approximately ninety percent compared to prior bypassing agent therapy, though it does not restore normal coagulation and cannot be monitored by standard factor assays, creating challenges for surgical management and breakthrough bleeding treatment.

Gene therapy for hemophilia has emerged as a potentially curative approach, utilizing adeno-associated viral vectors to deliver functional factor VIII or factor IX genes to hepatocytes, achieving sustained factor expression in clinical trials that has permitted discontinuation of prophylactic therapy in many adult participants. The phase three trials of valoctocogene roxaparvovec for hemophilia A and etranacogene dezaparvovec for hemophilia B demonstrated sustained factor expression and dramatic reductions in annualized bleeding rates, with the hemophilia B trial achieving mean factor IX levels of approximately forty percent of normal one year after infusion, though durability beyond two years and pediatric safety remain under investigation. The application of gene therapy to children awaits resolution of concerns regarding insertional mutagenesis, liver toxicity, and the implications of irreversible genetic modification in growing patients, with current trials restricted to adults, though the theoretical appeal of curing hemophilia before joint damage accrues drives ongoing research into pediatric-specific approaches. The psychosocial dimensions of hemophilia management, including the burden of intravenous access, the anxiety surrounding bleeding episodes, the restrictions on physical activity, and the transition to self-management in adolescence, require attention equal to that given to factor levels, with studies demonstrating that comprehensive care through hemophilia treatment centers improves outcomes and reduces costs compared to fragmented care.

DISCUSSION

The contemporary management of hemophilia in children embodies both the triumphs and the persistent challenges of modern pediatric hematology, as a disease that once condemned boys to short, disabled lives has become a chronic condition compatible with normal survival, yet one that continues to extract significant costs in terms of treatment burden, psychological stress, and health care resource utilization. The transformation from on-demand therapy to primary prophylaxis represents one of the great success stories of evidence-based medicine, demonstrating that preemptive factor replacement can prevent the joint destruction that historically defined severe hemophilia, yet the optimal intensity of prophylaxis remains debated, with some experts advocating for higher trough levels to prevent all bleeding including subclinical microhemorrhages that may contribute to long-term joint damage, while others emphasize the burden of frequent infusions and the diminishing returns of escalating doses. The development of extended half-life products has reduced infusion frequency, potentially improving adherence and quality of life, though pharmacokinetic variability among patients necessitates individualized dosing guided by trough level monitoring, and the higher per-unit cost of these products has limited their availability in resource-constrained settings, creating global disparities in access to optimal care. The emergence of emicizumab has fundamentally altered the treatment landscape for hemophilia A, offering subcutaneous prophylaxis that dramatically reduces bleeding frequency without the need for intravenous access, yet its inability to restore normal coagulation, its interference with standard laboratory assays, and its high cost present challenges that require ongoing clinical experience to resolve. The promise of gene therapy, with its potential to provide sustained factor expression and functional cure, represents the culmination of decades of research, yet pediatric application awaits resolution of safety concerns including liver toxicity, insertional mutagenesis, and the ethical complexities of irreversible genetic modification in children who cannot provide informed consent, while the high cost of vector production raises questions about equitable access in low- and middle-income countries where the majority of hemophilia patients reside. The psychosocial burden of hemophilia, including the anxiety of parents watching for bleeding signs, the pain of repeated venipunctures, the social isolation of activity restrictions, and the transition to self-management in adolescence, demands comprehensive care that extends beyond factor replacement to include psychological support, social work intervention, and peer connection through organizations such as the National Hemophilia Foundation and the World Federation of Hemophilia. The global disparities in hemophilia care, with life expectancy in high-income countries approaching normal while patients in low-income countries continue to die from preventable bleeding, represent a moral challenge to the international medical community, requiring innovative approaches including generic factor production, South-South collaboration, and health system strengthening to ensure that advances in hemophilia therapy benefit all children regardless of geography or socioeconomic circumstance.

CONCLUSION

Hemophilia in children, once a fatal affliction that shaped royal succession and family tragedies, has been transformed into a chronic disease compatible with normal survival and near-normal quality of life through the remarkable convergence of molecular genetics, protein engineering, and clinical innovation. The contemporary management of hemophilia rests upon the pillars of early diagnosis through factor assays and genetic testing, primary prophylaxis initiated before joint bleeding begins, comprehensive care through specialized treatment centers, and emerging therapies including extended half-life concentrates, non-factor agents such as emicizumab, and potentially curative gene therapy. The development of inhibitors remains the most serious complication of factor replacement therapy, requiring immune tolerance induction and bypassing agents, while the psychosocial dimensions of treatment burden, activity restriction, and transition to self-management necessitate family-centered, multidisciplinary approaches that address the whole child rather than merely the factor level. The future of hemophilia care lies in the realization of personalized medicine, where genetic diagnosis guides therapeutic selection, pharmacokinetic monitoring optimizes dosing, and gene therapy offers the possibility of cure, though the ethical imperative of global equity demands that these advances reach the majority of hemophilia patients who reside in resource-limited settings. As research continues to push the boundaries of what is possible, the enduring challenge remains to ensure that every child with hemophilia, regardless of where they are born, has access to the care that transforms a potentially devastating diagnosis into a manageable chronic condition, allowing them to run, play, and dream without the constant shadow of uncontrolled bleeding.

REFERENCES

1. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1-e47.

2. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. New England Journal of Medicine. 2007;357(6):535-544.

3. Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. New England Journal of Medicine. 2017;377(22):2094-2104.

4. Pasi KJ, Rangarajan S, Mitchell N, et al. Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A. New England Journal of Medicine. 2020;382(1):29-40.

5. Pipe SW, Leebeek FWG, Recht M, et al. Gene therapy with etranacogene dezaparvovec for hemophilia B. New England Journal of Medicine. 2023;388(8):706-718.

6. Blanchette VS, Key NS, Ljung LR, et al. Definitions in hemophilia: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 2014;12(11):1935-1939.

7. Hay CRM, DiMichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood. 2012;119(6):1335-1344.

8. Fischer K, Ljung R. Management of inhibitors in hemophilia A and B. Haemophilia. 2015;21(Suppl 5):76-82.

9. van den Berg HM, Fischer K, Carcao M, et al. Timing and frequency of joint bleeds in subjects with severe haemophilia A and B. Haemophilia. 2013;19(3):353-358.

10. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia. 2003;9(4):418-435.